Esophageal squamous cell carcinoma market is predicted to reach USD 1.45 billion at a CAGR of 8.16% during the forecast period 2023-2032

Esophageal Squamous Cell Carcinoma Market Highlights

The global esophageal squamous cell carcinoma market is accounted to register a CAGR of 8.16% during the forecast period and is estimated to reach USD 1.45 billion by 2032.

Achalasia patients have a higher risk of esophageal squamous cell carcinoma than the general population, the increasing prevalence of achalasia aid market growth. Achalasia affects 9 to 10 people per 100,000 people worldwide each year, according to the journal Annals of Esophagus. Achalasia can also cause food retention, which can result in bacterial overgrowth, irritation, and chronic inflammation, a pathophysiological process that has been linked to squamous cell carcinoma. Furthermore, two recent meta-analyses discovered that the incidence rate of squamous cell carcinoma in achalasia patients ranges from 1.36/1,000 patients-years to 3.12/1,000 patients-years, with risks of 1.5% and 2.8%, respectively. further propels market growth.

Rising public awareness of the availability of drugs and treatment for esophageal squamous cell carcinoma is expected to drive market growth. Additionally, awareness is essential for prevention, early detection, targeted therapy, and effective treatment. People who are aware of esophageal squamous cell carcinoma and its symptoms are more likely to undergo screenings, tests, and check-ups.

As a result, rising achalasia prevalence, increased research activities and product approvals, and rising health awareness will aid in the growth of the esophageal squamous cell carcinoma market.

Key Players

MRFR recognizes the following companies as the key players in the global esophageal squamous cell carcinoma market— F. Hoffmann-La Roche Ltd, AstraZeneca, Chia Tai Tianqing, Pharmaceutical Group Co. Ltd., Seagen Inc., Eli Lilly and Company, Glaxosmithkline Plc, Novartis AG, Beijing Shenzhou Cell Biotechnology Group Co., Ltd., and Jacobio Pharmaceuticals Group Co., Ltd.

Segment Analysis

The global esophageal squamous cell carcinoma market has been segmented based on diagnosis and treatment, and end user.

On the basis of diagnosis and treatment, the market is segmented into diagnosis and treatment. diagnosis is further segmented into endoscopy, CT scan, esophagram, positron emission tomography (PET) and others. Likewise, treatment is further segregated into surgery, chemotherapy, radiotherapy, immunotherapy, and others The treatment segment was attributed to holding the largest market share of 0.44 billion USD in 2022 revenue as estimated by MRFR analysts. the increasing prevalence of cancer, introduction of new highly effective medications with lower secondary effects and rising demand for chemotherapy for the market's expansion.

Based on end user, the global esophageal squamous cell carcinoma market has been segmented into segmented into hospitals, specialty centers and others. The hospital segment was expected to hold the largest market share in 2022.

Browse In-depth Market Details [Table of Content, List of Figures, List of Tables] of Esophageal Squamous Cell Carcinoma Market Research Report

Regional Analysis

The global esophageal squamous cell carcinoma market, based on region, has been divided into North America, Europe, Asia-Pacific, and the Rest of the World. North America consists of US and Canada. The Europe esophageal squamous cell carcinoma market comprises Germany, France, the UK, Italy, Spain, and the rest of Europe. The esophageal squamous cell carcinoma market in Asia-Pacific has been segmented into China, India, Japan, Australia, South Korea, and the rest of Asia-Pacific. The Rest of the world’s esophageal squamous cell carcinoma market comprises of Middle East, Africa, and Latin America.

the rising prevalence of esophageal cancer which is raising the demand for the esophageal squamous cell carcinoma treatment market are expected to foster North America’s market growth.

Moreover, the Europe market has been persistently growing owing to a due to the rising inclination towards smoke, tobacco, and drink is driving up demand for an advanced treatment option for esophageal squamous cell carcinoma. Moreover, rising healthcare expenditure is also expected to support the growth of the market.

Additionally, market factors, such as the rising incidence of esophageal squamous cell carcinoma, and the high population of tobacco smoking and alcohol drinking in this region in the Asia-Pacific region and are driving the region’s growth.

Furthermore, the rest of the world's patient portal market is divided into the Middle East, Africa, and Latin America. The major factors driving the growth of esophageal squamous cell carcinoma market in the region are the due to strong epidemiological factors, and improving healthcare facilities, increasing awareness about healthy lifestyles. Moreover, improving medical infrastructure in developing and underdeveloped countries, and growing inclination towards advanced treatment solution.

Key Findings of the Study

• The global esophageal squamous cell carcinoma market is expected to reach USD 1.45 billion by 2032, at a CAGR of 8.16% during the forecast period.


• The Europe region accounted for the fastest-growing global market, owing due to the rising inclination towards smoke, tobacco, and drink is driving up demand for an advanced treatment option for esophageal squamous cell carcinoma.


• Based on end user, the hospitals segment was attributed to holding the largest market in 2022, with an approximate USD 0.62 billion.


• Hoffmann-La Roche Ltd, AstraZeneca, Chia Tai Tianqing, Pharmaceutical Group Co. Ltd., Seagen Inc., Eli Lilly and Company, Glaxosmithkline Plc, Novartis AG, Beijing Shenzhou Cell Biotechnology Group Co., Ltd., and Jacobio Pharmaceuticals Group Co., Ltdare the key market players.